A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Getting a cold once or twice a few months is normal, but what about a persistently blocked nose that lingers for weeks and ...

Probation officials said youths and staff members were hospitalized after a 'suspected overdose and possible exposure to an ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

Vending machines throughout Denver have distributed more than 1,800 free boxes of the overdose reversal medication naloxone since they debuted in April.

The potent synthetic opioid, developed for large animals, threatens to reverse Michigan's recent progress in reducing ...